Wall Street brokerages expect Intellia Therapeutics Inc (NASDAQ:NTLA) to announce $12.73 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Intellia Therapeutics’ earnings, with the lowest sales estimate coming in at $7.12 million and the highest estimate coming in at $25.40 million. Intellia Therapeutics reported sales of $7.32 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 73.9%. The business is expected to report its next earnings report on Tuesday, October 30th.
According to Zacks, analysts expect that Intellia Therapeutics will report full-year sales of $41.09 million for the current fiscal year, with estimates ranging from $29.59 million to $58.40 million. For the next fiscal year, analysts forecast that the company will post sales of $43.64 million per share, with estimates ranging from $25.56 million to $58.30 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Wednesday, August 1st. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The firm had revenue of $7.68 million for the quarter, compared to the consensus estimate of $6.39 million. During the same quarter in the previous year, the firm earned ($0.45) earnings per share. The company’s quarterly revenue was up 30.2% compared to the same quarter last year.
NTLA has been the topic of several recent analyst reports. Cann reissued a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday, May 1st. TheStreet downgraded shares of Intellia Therapeutics from a “c-” rating to a “d” rating in a research note on Monday, May 7th. Chardan Capital raised shares of Intellia Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, May 15th. BidaskClub raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 16th. Finally, Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 18th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $34.14.
In other Intellia Therapeutics news, insider John M. Leonard sold 8,400 shares of the stock in a transaction dated Monday, May 14th. The shares were sold at an average price of $24.00, for a total transaction of $201,600.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jean Francois Formela sold 6,686 shares of the stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $31.17, for a total transaction of $208,402.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,458 shares of company stock worth $764,361. Company insiders own 12.80% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN boosted its holdings in shares of Intellia Therapeutics by 108.0% in the 4th quarter. Wells Fargo & Company MN now owns 34,767 shares of the company’s stock valued at $668,000 after buying an additional 18,050 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Intellia Therapeutics by 1.9% in the 4th quarter. BlackRock Inc. now owns 1,710,947 shares of the company’s stock valued at $32,885,000 after buying an additional 31,662 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Intellia Therapeutics by 42.5% in the 4th quarter. Geode Capital Management LLC now owns 195,925 shares of the company’s stock valued at $3,765,000 after buying an additional 58,411 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Intellia Therapeutics by 8.5% in the 4th quarter. Deutsche Bank AG now owns 41,744 shares of the company’s stock valued at $800,000 after buying an additional 3,279 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Intellia Therapeutics by 306.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 129,900 shares of the company’s stock valued at $2,497,000 after buying an additional 97,936 shares in the last quarter. Institutional investors own 59.81% of the company’s stock.
Intellia Therapeutics traded up $0.18, reaching $27.67, during mid-day trading on Tuesday, Marketbeat.com reports. 404,637 shares of the company’s stock traded hands, compared to its average volume of 665,178. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -14.72 and a beta of 2.93. Intellia Therapeutics has a 12-month low of $15.06 and a 12-month high of $35.99.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Featured Story: Market Capitalization
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.